This preprint is under consideration at European Journal of Medical Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Yousef Moradi
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objectives: This study aimed to systematically review the literature on the prevalence of Hepatitis C virus (HCV) and Hepatitis B virus (HBV) infections in transgender and LGBT people and determine their pooled estimates worldwide.
Methods: Databases (PubMed, Scopus, Web of Science, Embase, Ovid, Cochrane, PsycInfo) were searched from April 2000 to July 2021. The pooled, subgroup, and cumulative analyses were executed using the random-effects model in Stata 16.
Results: Ten studies, including eight studies on Four transgender people and two studies on 2150 LGBTs, were included. The pooled prevalence of HCV and HBV in all transgender populations globally were 9% (95%CI: 3- 15%) and 11% (95%CI: 2- 20%), respectively. The corresponding prevalence in male-to-female transgender people were estimated as 5% (95%CI: 1- 9%) and 6% (95%CI: 3- 10%), respectively. These estimates in American transgenders were 10% (95%CI: 5- 25%) and 16% (95%CI: 8- 23%), respectively.
Conclusion: This study was identified the overall prevalence of HBV and HCV infections in transgender people, which were higher than those in the general population. Thus, this group of sexual minorities was at higher risk for HBV and HCV infections, and it was necessary to develop, design, and implement a protocol for providing services related to HBV and HCV infections, such as a hepatitis B vaccination program and treatment of hepatitis C along with screening and designing appropriate interventions in transgender people.
Keywords
LGBT, Lesbian, Gay, Bisexual, Transgender, Hepatitis B, Hepatitis C, AIDS, Meta-Analysis, Blood-borne diseases, high-risk
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 02 Nov, 2021
No community comments so far
Reviews received
Received 17 Nov, 2021
Reviewers invited
Invitations sent on 17 Nov, 2021
Reviewer #2 agreed
On 16 Nov, 2021
Reviewer #3 agreed
On 16 Nov, 2021
Reviewer #1 agreed
On 16 Nov, 2021
Editor assigned
On 27 Oct, 2021
Submission checks complete
On 26 Oct, 2021
Editor invited
On 26 Oct, 2021
First submitted
On 26 Oct, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
Learn more about our company.
This preprint is under consideration at European Journal of Medical Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Yousef Moradi
Kurdistan University of Medical Science: Kurdistan University of Medical Sciences
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 02 Nov, 2021
No community comments so far
Reviews received
Received 17 Nov, 2021
Reviewers invited
Invitations sent on 17 Nov, 2021
Reviewer #2 agreed
On 16 Nov, 2021
Reviewer #3 agreed
On 16 Nov, 2021
Reviewer #1 agreed
On 16 Nov, 2021
Editor assigned
On 27 Oct, 2021
Submission checks complete
On 26 Oct, 2021
Editor invited
On 26 Oct, 2021
First submitted
On 26 Oct, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objectives: This study aimed to systematically review the literature on the prevalence of Hepatitis C virus (HCV) and Hepatitis B virus (HBV) infections in transgender and LGBT people and determine their pooled estimates worldwide.
Methods: Databases (PubMed, Scopus, Web of Science, Embase, Ovid, Cochrane, PsycInfo) were searched from April 2000 to July 2021. The pooled, subgroup, and cumulative analyses were executed using the random-effects model in Stata 16.
Results: Ten studies, including eight studies on Four transgender people and two studies on 2150 LGBTs, were included. The pooled prevalence of HCV and HBV in all transgender populations globally were 9% (95%CI: 3- 15%) and 11% (95%CI: 2- 20%), respectively. The corresponding prevalence in male-to-female transgender people were estimated as 5% (95%CI: 1- 9%) and 6% (95%CI: 3- 10%), respectively. These estimates in American transgenders were 10% (95%CI: 5- 25%) and 16% (95%CI: 8- 23%), respectively.
Conclusion: This study was identified the overall prevalence of HBV and HCV infections in transgender people, which were higher than those in the general population. Thus, this group of sexual minorities was at higher risk for HBV and HCV infections, and it was necessary to develop, design, and implement a protocol for providing services related to HBV and HCV infections, such as a hepatitis B vaccination program and treatment of hepatitis C along with screening and designing appropriate interventions in transgender people.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...